However, these methods are too complicated for general clinical use and usually focus on MHC I epitopes and not on inducing cytotoxic CD8+ T cell responses.[32, 39] The present study particularly harnessed tumor‐derived antigens loaded onto TEVs to ensure their neoantigen content and ensure their safe delivery to elicit a robust response in CD8+ T cells and thereby develop an effective personalized cancer vaccine. The gene discussed is CD8A; the disease is neoplasm.